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SUMMARY 
14C-Labelled clofibric acid and fenofibric acid were administered p.o .. to 200 g 
male and female rats. After 10 h, liver nuclear DNA and protein were isolated and 
the radioactivity was determined. Binding to protein was clearly measurable 
whereas no binding to DNA could be detected from any drug. A comparison of the 
Iimit of detection of such DNA binding with well-known chemical carcinogens 
revealed that the known hepatocarcinogenicity of clofibrate cannot be based upon 
an initiating, DNA damaging, mode of action but must be due to other, non-
genotoxic, mechanisms such as peroxisome proliferation, hepatomegaly, or cyto-
toxicity due to protein binding. The risk assessment in man and the interpretation of 
the carcinogenicity data for rodents are discussed. 
INTRODUCTION 
Clofibrate (ethyl-a-p-chlorophenoxyisobutyrate), the most \Videly used 
hypolipidemic drug in the U.S. and Europe [1] has been shown to induce 
hyperplastic and neoplastic changes in rat liver (2, 3]. Epidemiologie investigations 
in man have revealed an increased incidence of various malignant neoplasms but the 
findings are not statistically significant [4). Fenofibrate (isopropyl-{4' (p .. chloro" 
benzoyl)-2·phenoxy-2-methyl)-propionate; procetofene; Lipanthyf!l ; LF 178), 
Please send correspondence to: Dr. W.K. Lutz, Institute ofToxicology, ETH/Univ. of Zürich, CH-8603 
Schwerzenbach (Switzerland). 
Abbreviation: CBI, covalent binding index. 
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structurally related to clofibrate, is about 6 times more active as a hypolipidemic 
agent [5). No reports on long-term carcinogenicity studies with fenofibrate have 
been published. 
These two and other hypolipidemic drugs cause a marked increase of liver 
peroxisomes in rodents accompanied by a marked hepatomegaly [6-8], and it was 
postulated in a recent report [9] that peroxisome proliferators might represent a 
novel class of carcinogens. 
One main characteristic of mosi organic chemical carcinogens is their ability to 
undergo covalent interactions with the DNA of the target organ. It has been shown 
that hypolipidemic peroxisome proliferators a.re negative in the Ames test and in the 
lymphocyte [lH]thymidine assay [ 1 0]. Formation of reactive metabolites and their 
interaction with macromolecules in animals has not yet been studied. 
We report here that clofibric acid (I) or fenofibric acid (Il), the pharmacologically 
active forms [ 111 and most important metabolites of clofibrate and fenofibrate {12], 
respectively, do not interact with rat liver DNA after oral administration. 
CH3 
-o- I •+o ct o-c-c, 1 OH 
CH3 
I 
MATERIALS AND METHODS 
n 
[ 14C]Clofibric acid (I) was prepared by the Commissariat a l'Energie Atomique, 
Gif-sur-Yvette, France, with a specific activity of 22 mCi/m.mol. [14C]Fenofibric 
acid (II) was synthesized by Luu Duc, Laboratoire de Chimie et de Pharmacie, 
Universite Scientifique et deMerleeine de Grenoble, La Trouche, France, with a 
specific activity of 5.82 mCi/mmol. The compounds were Iabeiied at the positions 
indicated in the structural formula. The purity was >97fr/o, as determined by thin· 
layer chromatography on silicagel plates with benzene-ethanol-acetic acid, 
80:12:5. For the low-dose experiment, the Iabelied compounds were used undiluted. 
For the high-dose experiment, they were diluted with inactive material (Laboratoires 
Fournier S.A., Dijon, France) to specific activities of 2.63 mCi/mmol and 2.82 
mCi/mmol for the clofibric and fenofibric acid, respectively. The compounds were 
administered p.o. in 0.5 ml dimethyl sulfoxide to Sprague-Dawley-derived SIV 50 
rats weighing about 200 g. They were fed with Nafag laboratory chow No 890 
(Nafag AG, Gossau, Switzerland) and were given tap water ad lib. 10 h after the 
administration, the rats were killed by open-heart puncture under ether anesthesia, 
the livers were excised, and a nuclear fraction was prepared according to Viviani et 
al. [13]. Nuclear protein was precipitated 4 times with acetone and purified by 
dialysis and one more acetone precipitation step [14]. DNA was isolated by the 
307 
method of Markov and lvanov [15] with some modifications [14]. The highly puri-
fied DNA (less than 0.1 o/o protein) was dissolved in 4 ml 0.014 M phosphate buffer 
(pH 6.8) and the scintillation counting was performed after addition of 10 ml Insta-
Gel (Packard Instruments, Downers Grove, IL, USA). The amount of DNA was 
determined by assuming an absorbance of 20 at 260 nrn for a solution of 1 mg 
DNA/ml. The protein was dissolved in 4 ml 1 OJo sodium dodecyl sulfate and counted 
by adding 1 ml to 10 ml Insta-GeL The amount of protein was measured by the 
method of Lowry et al. [16]. 
RESULTS AND DISCUSSION 
Compounds I and II, both 14C-labelled in the indicated position, were 
administered in low and high dose Ievels by gastric intubation to young adult rats. 
Nuclear DNA and protein were isolated from the livers after I 0 h and the radio-
activity of the macromolecules was determined. Whereas on the protein a radio-
activity in the order of 9 to 78 dpm/mg could be detected, the corresponding DNA 
values were just above the Iimit of detection (clofibric acid, high dose) or not 
measurable at all (all other cases) (Table I). 
Two dose levels were used in our binding experiments to detect possible saturation 
of metabolic pathways which might Iead to qualitative changes in the pattern of 
metabolites. 
The minute radioactivity detected on the DNA after clofibrate administration 
most probably does not indicate covalent binding of the drug to DNA but is due to 
biosynthetic incorporation of radioactivity. After oral administration of clofibric 
acid Iabelied at the terminal carboxyl group, 0.850Jo of the dose (high-dose 
experiment) was exhaled within 10 h as 14C02. C02 is one of the precursors for the 
purine biosynthesis so that the radioactivity detected on the DNA might weH have 
been incorporated. A control experiment was therefore performed: After oral 
administration of 15 mg/kg 14CH30H to rats, 80o/o of the radioactivity was exhaled 
as 14C02. The radioactivity which was incorporated into liver DNA, 12 h after this 
administration, corresponded to an apparent CBI of 170. These results were 
compatible with the above-mentioned hypothesis. With fenofibric acid, the Iabel is 
not in the terminal carboxyl group and a release of radioactivity into the pool of 
nucleic acid precursors is much less likely. This is in agreement with the much 
smaller fraction of 0.06o/o of the radioactive dose that is exhaled as 14C02 • 
In order to compare chemieals of varying DNA-binding abilities, the binding 
potency is expressed as a CBI = DNA damage/ dose [17]. The strongest hepato-
carcinogenic compounds with a genotoxic, initiating mode of action, e.g. aflatoxin 
Bt or dimethylnitrosamine, exhibit a CBI in the order of 103 to 104. Moderate 
hepatocarcinogens like 2-acetylaminofluorene and vinyl chloride show a CBI of 
about 1 ()2. As estimated from the long-term carcinogenicity data with clofibrate [3], 
and by using a linear relationship between carcinogenicity and CBI [ 18], a CBI of 10 
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would be expected for clofibrate if the mode of carcinogenic action of this drug were 
by DNA binding. However, the actually measured maximum possible CBI for 
clofibric acid, 0.15, is about 50 times below that value and is probably even lower if 
the biosynthetic part of the radioactivity is deducted. A genotoxic mode of the 
carcinogenic action is therefore unlikely and a non-genotoxic activity seems to be 
the reason for the observed liver tumors in the rat after treatment with clofibrate. 
The Iimit of detection of a DNA binding by fenofibric acid is another factor of 5 
lower. Together with the knowledge that therapeutic doses with this drug are about 
6 times lower than with clofibric acid [5], a maximum possible DNA darnage (CBI 
x dose) from fenofibric acid is therefore regarded negligible and a potential 
carcinogenicity of this drug must be due to non-genotoxic mechanisms. 
Protein binding is notasweil correlated with tumorigenicity as is DNA binding 
[ 19]. Protein binding tends to Iead to cytotoxicity and it is conceivable that the 
regenerating processes elicited from a high dose of a cytotoxic drug might have a 
promoting effect on any pre-existing pre-cancerous lesion set by ubiquitous 
genotoxic agents. 
The present data exclude somatic mutations as a carcinogenic mode of action of 
these two drugs. A risk assessment for man must therefore be based upon their 
cancer-promotive activities. Many other frequently -used compounds such as 
phenobarbital or halogenated pesticides show a similar mode of action. Threshold 
Ievels, non-linear dose-tumor relationships and a strong correlation with cell 
metabolism are more likely to be found with promoting activities than with 
initiating, genotoxic compounds. An extrapolation of any 'carcinogenicity data from 
rats to man must therefore await a comparison over a wide dose range of a number 
of biochemical effects of these drugs, viz., induction of microsomal enzymes, 
hypertrophy and hyperplasia of the Ii ver. 
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